Semaglutide News and Research

Latest Semaglutide News and Research

PYY hormone may offer effective treatment for type 2 diabetes

Researchers at the Norwegian University of Science and Technology and Oxford University have found a hormone that may offer an effective treatment for type 2 diabetes.

20 May 2016

Bruker showcases new products, analytical solutions for improved performance at Analytica 2016

This week at Analytica 2016, Bruker is showcasing new products and analytical solutions for improved performance and customer experience in pharmaceutical, industrial and applied markets.

From Bruker BioSpin - NMR, EPR and Imaging 11 May 2016

Study helps discover new treatments for type 2 diabetes in men with low testosterone

Doctors have long known that men with low testosterone are at greater risk for developing type 2 diabetes. For the first time, researchers have identified how testosterone helps men regulate blood sugar by triggering key signaling mechanisms in islets, clusters of cells within the pancreas that produce insulin. The findings, co-authored by Tulane University researchers, are published in the journal

29 Apr 2016

GLP-1 receptor agonist may benefit high-risk diabetes

Research shows that using a glucagon-like peptide-1 receptor agonist instead of a rapid-acting insulin analogue at mealtimes can reduce glycaemic variability in high-risk patients with Type 2 diabetes.

26 Apr 2016

Study offers clearer understanding of how obese people can sustain weight loss

Maintaining a stable weight loss is the biggest struggle for obese individuals, yet new research from University of Copenhagen have allowed researchers new insights into the complex processes involved in obesity and especially weight loss in obesity. It is now possible to offer overweight people a clearer understanding of how to sustain weight loss.

16 Apr 2016

Newly developed light-activated tool could pave way for new generation of anti-diabetic drugs

Researchers have developed a light-activated tool to show how drugs need to be adapted to combat type 2 diabetes.

12 Apr 2016

SCIEX and QPS Holdings enter collaboration to establish the BioBA solution for bioanalysis of biologics

SCIEX, a global leader in life science analytical technologies, and QPS Holdings, LLC (QPS), a leading global full-service Contract Research Organization (CRO), today announced a collaboration to advance Hybrid LBA –LCMS, a workflow for routine biologics quantification. Under the agreement, QPS Holdings will deploy the SCIEX BioBA Solution, the first end-to-end and most complete solution for bioanalysis of biologics.

6 Apr 2016

Liraglutide drug makes highly desirable foods less appealing to people

Understanding the motivations that drive humans to eat is an important consideration in the development of weight loss therapies. Now a study led by researchers at Beth Israel Deaconess Medical Center helps explain how the diabetes and weight loss drug liraglutide acts on brain receptors to make enticing foods seems less desirable.

5 Apr 2016

Incretin-based drugs do not increase risk of heart failure

Incretin-based drugs, a type of medication used to treat type 2 diabetes, do not increase the risk of being hospitalized for heart failure relative to commonly used combinations of oral anti-diabetic drugs, according to a new study published in the New England Journal of Medicine.

25 Mar 2016

BioAgilytix announces acquisition of IPM Biotech

BioAgilytix, a leading provider of contract bioanalytical testing services specializing in large molecule bioanalysis, has announced the acquisition of IPM Biotech, a German-based bioanalytical contract research laboratory renowned for its expertise in large molecule bioanalysis, particularly in the area of immunogenicity.

18 Mar 2016

Drug combination improves glucose control in Type 2 diabetes patients

A multinational clinical trial led by UT Southwestern Medical Center and others found that injection of a new long-acting insulin combined with another drug improves glucose control in patients with Type 2 diabetes and, additionally, is associated with weight loss.

2 Mar 2016

IDegLira injections more effective than traditional insulin injections in treating type-2 diabetes patients

More than two-thirds of all type-2 diabetes patients do not achieve good control of their disease with the first-line medication metformin combined with second-line insulin shots.

2 Mar 2016

Isomaltulose more suitable than table sugar for people with type 2 diabetes

Potsdam-Rehbruecke - Like sucrose (table sugar), the natural disaccharide isomaltulose (PalatinoseTM) consists of glucose and fructose, but it is apparently more suitable for people with type 2 diabetes with regard to regulating blood glucose levels.

17 Feb 2016

Penn investigators explore new treatment option for cocaine dependence

In the ongoing fight against drug addiction, researchers from the University of Pennsylvania's School of Nursing and Perelman School of Medicine have discovered a unique application for an FDA-approved drug currently used for obese patients and type 2 diabetics: treatment for cocaine dependence.

11 Feb 2016

Study provides new insight into complex interchange that can raise blood levels of fat in type 1 diabetes

Researchers have new insight into the complex interchange that can raise blood levels of unhealthy lipids, or fat, in type 1 diabetes, and early evidence that a drug under study to block cancer cell growth can restore healthier levels.

8 Feb 2016

UM SOM selected to work with BARDA to develop radiologic and nuclear countermeasures

University of Maryland School of Medicine Department of Radiation Oncology Chair and Professor William F. Regine, MD, FACR, FACRO, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that researchers at the UM SOM have been selected as key contractors by the Biomedical Advanced Research and Development Authority, for its Radiation Nuclear Animal Model Development program.

18 Jan 2016

Jubilant Biosys, Sanofi partner to develop small molecule inhibitors in metabolic disorders therapeutic area

Jubilant Biosys Ltd, a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd, and Sanofi Deutschland GmbH, Frankfurt, Germany, announced a strategic alliance to discover and develop small molecule inhibitors for multiple targets in the metabolic disorders therapeutic area.

7 Jan 2016

Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

Rani Therapeutics announced today that it has entered into a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, to evaluate Rani's novel oral drug delivery platform. The companies have agreed to conduct feasibility studies over the next two years, in which Rani will test select biologic molecules in the area of metabolic disease to evaluate the oral delivery of these molecules.

6 Jan 2016

New class of diabetes drugs differs in efficacy and safety profiles, shows new research

Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) differ in their efficacy and safety profiles, according to new research by the University of Leicester.

10 Dec 2015

TSRI scientists use new drug discovery technique to identify anti-diabetes compound

Scientists from The Scripps Research Institute have deployed a powerful new drug discovery technique to identify an anti-diabetes compound with a novel mechanism of action.

8 Dec 2015

Semaglutide News and Research

Latest Semaglutide News and Research

PYY hormone may offer effective treatment for type 2 diabetes

Bruker showcases new products, analytical solutions for improved performance at Analytica 2016

Study helps discover new treatments for type 2 diabetes in men with low testosterone

GLP-1 receptor agonist may benefit high-risk diabetes

Study offers clearer understanding of how obese people can sustain weight loss

Newly developed light-activated tool could pave way for new generation of anti-diabetic drugs

SCIEX and QPS Holdings enter collaboration to establish the BioBA solution for bioanalysis of biologics

Liraglutide drug makes highly desirable foods less appealing to people

Incretin-based drugs do not increase risk of heart failure

BioAgilytix announces acquisition of IPM Biotech

Drug combination improves glucose control in Type 2 diabetes patients

IDegLira injections more effective than traditional insulin injections in treating type-2 diabetes patients

Isomaltulose more suitable than table sugar for people with type 2 diabetes

Penn investigators explore new treatment option for cocaine dependence

Study provides new insight into complex interchange that can raise blood levels of fat in type 1 diabetes

UM SOM selected to work with BARDA to develop radiologic and nuclear countermeasures

Jubilant Biosys, Sanofi partner to develop small molecule inhibitors in metabolic disorders therapeutic area

Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

New class of diabetes drugs differs in efficacy and safety profiles, shows new research

TSRI scientists use new drug discovery technique to identify anti-diabetes compound

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Semaglutide News and Research

Latest Semaglutide News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in